Non-insulin demanding type 2 diabetes
Conditions
Interventions
Trade Name: Nateglinide 120 mg
Starlix 120
Pharmaceutical Form: Tablet
INN or Proposed INN: NATEGLINIDE
CAS Number: 105816044
Concentration unit: mg milligram(s)
Concentration type: equal
Concentratio
Sponsors
Johan Wolfgang Goethe Universität - Department of Internal medicine I, Division Endocrinology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Typ 2 Diabetes, male or female Age 18 – 80 years Control: young, healthy volunteers no diabetes, IFG or IGT stated in the case history Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Active, consuming diseases (cancer, HIV) Renal failure (creatinine >1,5 mg/dl) Liver diseases (AST, ALT >1,5x ULN) Psychiatric diseases Insulin therapy Pregnancy or missing contraception in childbearing ange, nursing contraindication to Nateglinide Typ 1 diabetes Unable or unwilling to comply with study Maltose-Malabsorption acut gastrointestinal infection gut surgery in the case history fever
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Evaluation of the ß-cell-secretory-capacity by giving 120 mg Nateglinide and 50 g glucose in individuals with type 2 diabetes in a modyfied oral glucose tolerance test.;Secondary Objective: Classification of patients with type 2 diabetes;Primary end point(s): glucose, Insulin, C-peptide - AUC, - max. level and time of max. level Insulin resistence: HOMA-IR, QUICKI, ISI | — |
Countries
Germany
Outcome results
None listed